In a clinical trial evaluating the efficacy of inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) in ER-positive BC, short-term reduction in PIK3CA ctDNA levels predicted prognosis and treatment response (15). This evidence concerns the gene CDK4 and breast cancer.